Novartis officials believe the sale will bolster its Sandoz business after a number of recent mergers shook up the generic drug industry, according to the article.
The deal has not yet been finalized, leaving room for other interested parties to make a potential offer. NJBiz reports interested parties include: Thousand Oaks, Calif.-based Amgen, Basel, Switzerland-based Roche Holding, London-based AstraZeneca and New York City-based Pfizer.
More articles on transactions and valuations:
IU Health to operate Frankfurt Hospital
University of Kansas Hospital enters into joint venture with Stormont cancer center
Madera Community Hospital launches partnership with VEP Healthcare
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
